文献速递肝病消化道肿瘤与早癌

替诺福韦较恩替卡韦降低中国慢性HBV感染者肝癌风险

Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
PubMed 文献 · Gastroenterology · 2019-09-28

该回顾性研究纳入中国29350例慢性HBV感染初治患者,比较TDF与恩替卡韦对HCC风险的影响。

要点

  • 在中国慢性HBV感染初治患者中,TDF较恩替卡韦与更低的HCC风险相关。

核心结论

  • 在中国慢性HBV感染患者中,TDF治疗较恩替卡韦治疗与更低的HCC风险相关。

研究设计与样本

  • 回顾性研究纳入2008年1月至2018年6月连续成人慢性HBV感染初治患者,要求治疗至少6个月。
  • 共分析29350例患者,平均年龄52.9±13.2岁,男性18685例(63.7%)。
  • 1309例(4.5%)首选TDF,28041例(95.5%)首选恩替卡韦。
  • 采用倾向评分加权和1:5匹配平衡两组临床特征,Fine-Gray模型调整死亡和肝移植竞争风险。
  • 排除治疗前或治疗最初6个月内发生癌症或接受肝移植的患者。

主要发现

  • TDF组患者更年轻(平均43.2岁 vs 53.4岁),肝硬化比例更低(38例[2.9%] vs 3822例[13.6%])。
  • 中位随访3.6年(IQR 1.7-5.0年),TDF组8例(0.6%)、恩替卡韦组1386例(4.9%)发生HCC。

临床怎么用

  • 对于中国慢性HBV感染初治患者,选择TDF可能较恩替卡韦进一步降低HCC风险。

局限性

  • 本研究为回顾性分析,存在回顾性研究固有的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There have been conflicting results from studies comparing the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection treated with tenofovir disoproxil fumarate (TDF) vs those treated with entecavir. We compared the effects of TDF vs entecavir on HCC risk in a large cohort of patients with chronic HBV infection in China. METHODS: We performed a retrospective study of consecutive adults with chronic HBV infection who initially received treatment with entecavir or TDF, for at least 6 months, from January 2008 through June 2018. Patients who had cancers or liver transplantation before or within the first 6 months of treatment were excluded. Propensity score weighting and 1:5 matching were used to balance the clinical characteristics between the 2 groups. Fine-Gray model was used to adjust for competing risk of death and liver transplantation. RESULTS: We analyzed data from 29,350 patients (mean age, 52.9 ± 13.2 years; 18,685 men [63.7%]); 1309 were first treated with TDF (4.5%) and 28,041 were first treated with entecavir (95.5%). TDF-treated patients were younger (mean age, 43.2 years vs 53.4 years) and a lower proportion had cirrhosis (38 patients [2.9%] vs 3822 patients treated with entecavir [13.6%]). At a median follow-up time of 3.6 years after treatment began (interquartile range, 1.7-5.0 years), 8 TDF-treated patients (0.6%) and 1386 entecavir-treated patients (4.9%) developed HCC. Patients' clinical characteristics were comparable after propensity score weighting. TDF treatment was associated with a lower risk of HCC than entecavir treatment after propensity score weighting (weighted subdistribution hazard ratio, 0.36; 95% confidence interval 0.16-0.80; P = .013) and 1:5 matching (weighted subdistribution hazard ratio, 0.39; 95% confidence interval 0.18-0.84; P = .016). CONCLUSIONS: In a retrospective analysis of 29,350 patients with chronic HBV infection in China, treatment with TDF was associated with a lower risk of HCC than treatment with entecavir, over a median follow-up time of 3.6 years.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Yip TC, Wong VW, Chan HL, et al. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. Gastroenterology. 2019. PMID: 31574268. doi:10.1053/j.gastro.2019.09.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。